{"url_path":"/sec/inbp/8-k/2026-02-18/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-02-18","source_url":"https://www.sec.gov/Archives/edgar/data/1016504/0001437749-26-004553-index.html","accession_number":"0001437749-26-004553","cik":"0001016504","ticker":"INBP","issuer_name":"INTEGRATED BIOPHARMA INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1016504/0001437749-26-004553-index.html","primary_entity_key":"0001016504","primary_entity_name":"INTEGRATED BIOPHARMA INC"},"word_count":485,"has_tables":true,"body_markdown":"inbp20260217_8k.htm\n\nfalse\n0001016504\n\n0001016504\n\n2026-02-17\n2026-02-17\n\n**UNITED STATES**\n\n \n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n \n\nWASHINGTON, D.C. 20549\n\n \n\n_________________\n\n \n\n**FORM 8-K**\n\n \n\n \n\nCURRENT REPORT\n\nPURSUANT TO SECTION 13 OR 15(d) OF THE\n\nSECURITIES EXCHANGE ACT OF 1934\n\n \n\nDATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):\n\n \n\nFebruary 17, 2026\n\n________________\n\n \n\nINTEGRATED BIOPHARMA, INC.\n\n(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)\n\n \n\nDelaware\n\n \n\n(STATE OR OTHER JURISDICTION OF INCORPORATION)\n\n \n\n**               **\n\n**   001-31668**\n\n** 22-2407475**\n\n(COMMISSION FILE NUMBER)\n\n(I.R.S. EMPLOYER IDENTIFICATION NO.)\n\n \n\n**225 Long Avenue**\n\n**Hillside, New Jersey 07205**\n\n (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)\n\n \n\n**(973) 926-0816**\n\n(REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE)\n\n \n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):\n\n \n\n☐\n\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐\n\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) \n\n \n\n \n\n \n\nSecurities registered pursuant to Section 12(b) of the Exchange Act:\n\n \n\nTitle of each class\n\nTrading Symbol(s)\n\nName of each exchange on which registered\n\nNone\n\nNone\n\nNone\n\n \n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐\n\n     \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**1.01** **Entry into a Material Definitive Agreement.**\n\n \n\nOn February 17, 2026, Manhattan Drug Company, Inc. (\"MDC\"), a wholly owned subsidiary of Integrated Biopharma Inc. (the \"Company”), entered into a Fourth Amendment of Lease (the \"Amendment\") with Vitamin Realty Associates, LLC (\"Vitamin Realty\") to that certain Lease Agreement dated January 10, 1997, as amended on July 15, 2022 (the \"Original Lease\") with respect to certain office and warehouse space leased by MDC from Vitamin Realty.  The Amendment (i) decreases the total square footage MDC is leasing from Vitamin Realty from 116,175 square feet to 110,095 square feet, (ii) increases the annual basic rent amounts from $845,966 to $1,100,950 per annum, increasing three percent (3%) per annum, and extends the Termination Date to January 31, 2029.  In addition to the annual basic rent amounts, MDC will be obligated to pay its proportionate share of Vitamin Realty's operating expenses as additional rent.  All other terms of the Original Lease, as originally amended, remain in full force. \n\n \n\n \n\nVitamin Realty is 100% owned by the estate of Company's former chairman, and a major stockholder and the Co-Chief Executive Officers, who are also Directors of the Company."}